These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33284338)

  • 1. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
    Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
    JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
    van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
    Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
    Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
    Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
    van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
    Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
    Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.
    Kropp S; Lichtinghagen R; Winterstein K; Schlimme J; Schneider U
    Clin Lab; 2006; 52(5-6):237-40. PubMed ID: 16812949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.
    Lam LC; Garcia-Barcelo MM; Ungvari GS; Tang WK; Lam VK; Kwong SL; Lau BS; Kwong PP; Waye MM; Chiu HF
    Pharmacopsychiatry; 2001 Nov; 34(6):238-41. PubMed ID: 11778144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
    Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
    Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
    Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
    Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
    Dorado P; Peñas-Lledó EM; Llerena A
    Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
    Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
    Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.
    Ellingrod VL; Schultz SK; Arndt S
    Pharmacotherapy; 2002 Nov; 22(11):1416-9. PubMed ID: 12432967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
    Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
    Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.